PMID- 34052628
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 91
DP  - 2021 Oct
TI  - Two-center experience of cannabidiol use in adults with Dravet syndrome.
PG  - 5-8
LID - S1059-1311(21)00165-5 [pii]
LID - 10.1016/j.seizure.2021.05.014 [doi]
AB  - We describe real-world experience with cannabidiol (CBD) in adults with Dravet 
      Syndrome (DS) via GW Pharma early access programme at two UK neurology centres. 
      Adults with genetically-confirmed DS had CBD added to existing therapy, titrated 
      up to 20 mg/kg, as tolerated. The primary outcome measure was percentage 
      reduction in convulsive seizures. Secondary outcome measures included changes in 
      myoclonic seizures, and in cognition and quality of life as assessed by the 
      Caregiver Global Impression of Change (CGIC), and incidence of adverse events 
      (AEs). 18 adults (7 female; median age 27.5 years; range 20-51) were included. 
      Median follow-up was 176 days. In one, another antiseizure drug, clobazam, was 
      introduced during the programme. 3/17 (17.6%) had >30% reduction in convulsive 
      seizures (range: 87.5-100%). AEs occurred in all, the most common being 
      transaminitis (52.9%). Behavioural AEs led to discontinuation in 3/18 (16.7%), 
      including a seizure-free responder. In 7/18, CBD was stopped due to lack of 
      effect. 8/18 continue on treatment. Improvements in CGIC were reported in 41.2% 
      and 47.1% by physicians and families, respectively. 17.6% achieved sufficient 
      reduction in convulsive seizure frequency to qualify for NHS funding. AEs led to 
      withdrawal in only 16.7%. Close monitoring and dose adjustments of other 
      antiseizure drugs were necessary.
CI  - Copyright (c) 2021. Published by Elsevier Ltd.
FAU - Silvennoinen, Katri
AU  - Silvennoinen K
AD  - Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of 
      Neurology, Box 29, Queen Square, London WC1N 3BG, UK; Chalfont Centre for 
      Epilepsy, Chalfont St Peter, UK.
FAU - Ritter, Laura Mantoan
AU  - Ritter LM
AD  - Clinical Neurosciences Department, King's College Hospital NHS Foundation Trust, 
      Denmark Hill, London, UK.
FAU - Nashef, Lina
AU  - Nashef L
AD  - Clinical Neurosciences Department, King's College Hospital NHS Foundation Trust, 
      Denmark Hill, London, UK.
FAU - Hudgell, Kirsty
AU  - Hudgell K
AD  - St. Elizabeth's Centre, Much Hadham, Herts, UK.
FAU - Balestrini, Simona
AU  - Balestrini S
AD  - Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of 
      Neurology, Box 29, Queen Square, London WC1N 3BG, UK; Chalfont Centre for 
      Epilepsy, Chalfont St Peter, UK.
FAU - Sisodiya, Sanjay M
AU  - Sisodiya SM
AD  - Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of 
      Neurology, Box 29, Queen Square, London WC1N 3BG, UK; Chalfont Centre for 
      Epilepsy, Chalfont St Peter, UK.
FAU - Sidhu, Meneka K
AU  - Sidhu MK
AD  - Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of 
      Neurology, Box 29, Queen Square, London WC1N 3BG, UK; Chalfont Centre for 
      Epilepsy, Chalfont St Peter, UK.
LA  - eng
PT  - Journal Article
DEP - 20210524
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Anticonvulsants)
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 2MRO291B4U (Clobazam)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/therapeutic use
MH  - *Cannabidiol/therapeutic use
MH  - Clobazam/therapeutic use
MH  - *Epilepsies, Myoclonic/drug therapy
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Quality of Life
MH  - Young Adult
OTO - NOTNLM
OT  - Antiseizure medication
OT  - Epilepsy
OT  - Seizures
EDAT- 2021/05/31 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/05/30 20:54
PHST- 2021/03/17 00:00 [received]
PHST- 2021/04/26 00:00 [revised]
PHST- 2021/05/14 00:00 [accepted]
PHST- 2021/05/31 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2021/05/30 20:54 [entrez]
AID - S1059-1311(21)00165-5 [pii]
AID - 10.1016/j.seizure.2021.05.014 [doi]
PST - ppublish
SO  - Seizure. 2021 Oct;91:5-8. doi: 10.1016/j.seizure.2021.05.014. Epub 2021 May 24.